KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Revenue (2016 - 2024)

Palvella Therapeutics has reported Revenue over the past 9 years, most recently at $258000.0 for Q3 2022.

  • Quarterly Revenue fell 93.64% to $258000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $19.9 million through Sep 2022, down 8.88% year-over-year, with the annual reading at $31.4 million for FY2021, 31.4% up from the prior year.
  • Revenue was $258000.0 for Q3 2022 at Palvella Therapeutics, up from $230000.0 in the prior quarter.
  • Over five years, Revenue peaked at $17.3 million in Q4 2019 and troughed at $230000.0 in Q2 2022.
  • The 5-year median for Revenue is $8.3 million (2018), against an average of $7.1 million.
  • Year-over-year, Revenue tumbled 96.69% in 2018 and then soared 2778.33% in 2019.
  • A 5-year view of Revenue shows it stood at $600000.0 in 2018, then soared by 2778.33% to $17.3 million in 2019, then tumbled by 91.21% to $1.5 million in 2020, then soared by 456.19% to $8.4 million in 2021, then crashed by 96.94% to $258000.0 in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Revenue are $258000.0 (Q3 2022), $230000.0 (Q2 2022), and $11.0 million (Q1 2022).